Carrie Clark
Director of Genspect UK
Carrie Clark leads Genspect UK at a pivotal moment for British gender medicine. As the NHS presses ahead with a £10 million puberty blocker study, she brings forensic scrutiny to the Pathways research programme — asking whether Britain is genuinely learning from the Cass Review or quietly repackaging the same failed approach.
Carrie Clark is the Director of Genspect UK, the British arm of the international alliance that brings together clinicians, researchers, parents, and detransitioners concerned about the medicalisation of gender-distressed young people. She has been one of the most consistent UK voices calling for rigorous evidence standards in paediatric gender medicine — a position the Cass Review ultimately gave institutional force, even as the NHS's response to that review remains contested.
In episode four of Beyond Gender, The UK is Restarting a Puberty Blocker Trial Despite 25 Years of Evidence, Clark joined hosts Stella O'Malley and Mia Hughes to dissect the NHS's proposed Pathways research programme. Her argument was pointed: the £10 million study does not represent the clean break from Tavistock-era practice that post-Cass rhetoric promises. She examined the trial's flawed scientific premises and raised a specific procedural concern that will resonate with British listeners — that detransitioners were excluded from the consultations that shaped the study's design, the very people whose outcomes should be central to any honest reckoning with two decades of practice at the Gender Identity Development Service.
For a UK audience, Clark's critique goes beyond clinical methodology. It is a question of NHS accountability: whether a health service that the Cass Review found had operated without adequate clinical governance is capable of self-correction, or whether the Pathways programme represents institutional inertia dressed up as reform.
As Director of Genspect UK, Clark works across the intersection of policy, clinical standards, and family advocacy, ensuring that critical voices — particularly those of detransitioners — remain part of the conversation as Britain attempts to rebuild its approach to gender medicine from the ground up.
